Eli Lilly Delivers Stunning Q1 with EPS and Guidance Beats

Earnings
โดย StockStory·Read original
Summary · why it matters

Eli Lilly reported a stunning first quarter, beating analysts' EPS estimates and delivering an impressive beat of analysts' full-year EPS guidance estimates. The company posted revenues of $19.8 billion, up 55.5% year on year and 13.7% above expectations, making it the standout performer among the ten branded pharmaceuticals stocks tracked. Supernus Pharmaceuticals, by contrast, saw its stock fall 9.6% after a mixed quarter where full-year operating income guidance slightly topped expectations but EPS significantly missed. Zoetis was the weakest, with shares down 31.6% following a significant EPS miss and a slight miss on full-year EPS guidance.

Impact on stocks 5

Biotech & Genomic Medicine± Mixed · 3 stocks
Health Care▼ · 2 stocks
Zoetis Inc
ZTS
▼ NegativeCapitalrelevance

Shares down 31.6% following significant EPS miss and slight miss on full-year guidance.

© 2026 MarketDXNews